mutation positive non-small cell lung cancer: can we identify predictors of benefit from immune checkpoint inhibitors.
作者信息
Wang Ying, Ellis Peter
机构信息
Department of Oncology, McMaster University, Hamilton, ON, Canada.
出版信息
Ann Transl Med. 2017 Nov;5(21):424. doi: 10.21037/atm.2017.08.14.
Abstract
摘要
相似文献
1
mutation positive non-small cell lung cancer: can we identify predictors of benefit from immune checkpoint inhibitors.突变阳性非小细胞肺癌：我们能否识别出从免疫检查点抑制剂中获益的预测指标？
Ann Transl Med. 2017 Nov;5(21):424. doi: 10.21037/atm.2017.08.14.
2
Immune checkpoint inhibitors in EGFR-mutation positive TKI-treated patients with advanced non-small-cell lung cancer network meta-analysis.表皮生长因子受体（EGFR）突变阳性、接受酪氨酸激酶抑制剂（TKI）治疗的晚期非小细胞肺癌患者使用免疫检查点抑制剂的网状Meta分析
Oncotarget. 2019 Jan 4;10(2):209-215. doi: 10.18632/oncotarget.26541.
3
[Study Progression on Non-small Cell Lung Cancer with EGFR Mutation
Treated by Immune Checkpoint Inhibitors].[免疫检查点抑制剂治疗表皮生长因子受体（EGFR）突变的非小细胞肺癌的研究进展]
Zhongguo Fei Ai Za Zhi. 2018 Aug 20;21(8):641-648. doi: 10.3779/j.issn.1009-3419.2018.08.11.
4
Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer-A Meta-Analysis.《转移性 EGFR 突变非小细胞肺癌中免疫检查点抑制剂的Meta 分析》
J Thorac Oncol. 2017 Feb;12(2):403-407. doi: 10.1016/j.jtho.2016.10.007. Epub 2016 Oct 17.
5
Application of immune checkpoint inhibitors in EGFR-mutant non-small-cell lung cancer: from bed to bench.免疫检查点抑制剂在表皮生长因子受体（EGFR）突变的非小细胞肺癌中的应用：从临床到实验室研究
Ther Adv Med Oncol. 2020 Jun 9;12:1758835920930333. doi: 10.1177/1758835920930333. eCollection 2020.
6
Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC).表皮生长因子受体（EGFR）通路、Yes 相关蛋白（YAP）与非小细胞肺癌（NSCLC）中程序性死亡配体 1（PD-L1）的调控。
Int J Mol Sci. 2019 Aug 5;20(15):3821. doi: 10.3390/ijms20153821.
7
The Role of Angiogenesis Inhibitors in the Era of Immune Checkpoint Inhibitors and Targeted Therapy in Metastatic Non-Small Cell Lung Cancer.血管生成抑制剂在免疫检查点抑制剂和靶向治疗时代的转移性非小细胞肺癌中的作用。
Curr Treat Options Oncol. 2019 Feb 18;20(3):21. doi: 10.1007/s11864-019-0617-6.
8
Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions.表皮生长因子受体突变型非小细胞肺癌的免疫检查点抑制剂：当前的争议和未来的方向。
Lung Cancer. 2018 Jan;115:12-20. doi: 10.1016/j.lungcan.2017.11.009. Epub 2017 Nov 13.
9
Comparison of RECIST to immune-related response criteria in patients with non-small cell lung cancer treated with immune-checkpoint inhibitors.接受免疫检查点抑制剂治疗的非小细胞肺癌患者中RECIST与免疫相关反应标准的比较。
Cancer Chemother Pharmacol. 2017 Sep;80(3):591-598. doi: 10.1007/s00280-017-3396-4. Epub 2017 Jul 21.
10
Next-generation sequencing reveals novel resistance mechanisms and molecular heterogeneity in EGFR-mutant non-small cell lung cancer with acquired resistance to EGFR-TKIs.下一代测序揭示了 EGFR-TKI 获得性耐药的 EGFR 突变型非小细胞肺癌中的新型耐药机制和分子异质性。
Lung Cancer. 2017 Nov;113:106-114. doi: 10.1016/j.lungcan.2017.09.005. Epub 2017 Sep 12.
引用本文的文献
1
Musashi-2 (MSI2) regulates epidermal growth factor receptor (EGFR) expression and response to EGFR inhibitors in EGFR-mutated non-small cell lung cancer (NSCLC).Musashi-2（MSI2）在表皮生长因子受体（EGFR）突变的非小细胞肺癌（NSCLC）中调节表皮生长因子受体（EGFR）的表达及对EGFR抑制剂的反应。
Oncogenesis. 2021 Mar 15;10(3):29. doi: 10.1038/s41389-021-00317-y.
2
Simultaneous Single Cell Gene Expression and EGFR Mutation Analysis of Circulating Tumor Cells Reveals Distinct Phenotypes in NSCLC.循环肿瘤细胞的单细胞基因表达和 EGFR 突变分析揭示 NSCLC 的不同表型。
Adv Biosyst. 2020 Aug;4(8):e2000110. doi: 10.1002/adbi.202000110. Epub 2020 Jul 23.
3
Rationale for Lung Adenocarcinoma Prevention and Drug Development Based on Molecular Biology During Carcinogenesis.基于肺癌发生过程中分子生物学的肺腺癌预防及药物研发原理
Onco Targets Ther. 2020 Apr 14;13:3085-3091. doi: 10.2147/OTT.S248436. eCollection 2020.
4
Personalized therapy for lung cancer: striking a moving target.肺癌的个体化治疗：直击移动的目标。
JCI Insight. 2018 Aug 9;3(15). doi: 10.1172/jci.insight.120858.
本文引用的文献
1
Immune Checkpoint Inhibitors for Patients With Advanced Non-Small-Cell Lung Cancer: A Systematic Review.晚期非小细胞肺癌患者的免疫检查点抑制剂：一项系统评价
Clin Lung Cancer. 2017 Sep;18(5):444-459.e1. doi: 10.1016/j.cllc.2017.02.001. Epub 2017 Feb 16.
2
Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment.基于 EGFR-TKI 治疗后疾病进展时 T790M 状态的肿瘤免疫微环境和纳武利尤单抗在 EGFR 突变阳性非小细胞肺癌中的疗效。
Ann Oncol. 2017 Jul 1;28(7):1532-1539. doi: 10.1093/annonc/mdx183.
3
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.阿特珠单抗对比多西他赛用于既往治疗过的非小细胞肺癌患者（OAK）：一项3期、开放标签、多中心随机对照试验
Lancet. 2017 Jan 21;389(10066):255-265. doi: 10.1016/S0140-6736(16)32517-X. Epub 2016 Dec 13.
4
Predictive biomarkers for checkpoint inhibitor-based immunotherapy.基于检查点抑制剂的免疫疗法的预测性生物标志物。
Lancet Oncol. 2016 Dec;17(12):e542-e551. doi: 10.1016/S1470-2045(16)30406-5.
5
Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer-A Meta-Analysis.《转移性 EGFR 突变非小细胞肺癌中免疫检查点抑制剂的Meta 分析》
J Thorac Oncol. 2017 Feb;12(2):403-407. doi: 10.1016/j.jtho.2016.10.007. Epub 2016 Oct 17.
6
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.帕博利珠单抗对比多西他赛用于治疗后 PD-L1 阳性的、晚期非小细胞肺癌（KEYNOTE-010）：一项随机对照试验。
Lancet. 2016 Apr 9;387(10027):1540-1550. doi: 10.1016/S0140-6736(15)01281-7. Epub 2015 Dec 19.
7
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.纳武利尤单抗对比多西他赛治疗晚期非鳞状非小细胞肺癌
N Engl J Med. 2015 Oct 22;373(17):1627-39. doi: 10.1056/NEJMoa1507643. Epub 2015 Sep 27.
8
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.癌症免疫学。突变图谱决定非小细胞肺癌对程序性死亡受体1（PD-1）阻断治疗的敏感性。
Science. 2015 Apr 3;348(6230):124-8. doi: 10.1126/science.aaa1348. Epub 2015 Mar 12.
9
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.阿法替尼对比基于顺铂的化疗用于 EGFR 突变阳性肺腺癌（LUX-Lung 3 和 LUX-Lung 6）：两项随机、III 期临床试验总生存数据的分析。
Lancet Oncol. 2015 Feb;16(2):141-51. doi: 10.1016/S1470-2045(14)71173-8. Epub 2015 Jan 12.
10
Comprehensive molecular profiling of lung adenocarcinoma.肺腺癌的全面分子分析。
Nature. 2014 Jul 31;511(7511):543-50. doi: 10.1038/nature13385. Epub 2014 Jul 9.
Zotero 插件